Stack of newspapers on a computer keyboard.
Newsroom
News

Thermo Fisher Scientific Named to Fortune’s 2026 AIQ 75 for Adopting and Scaling AI

News-Fortune-AIQ-75

The recognition highlights Thermo Fisher Scientific’s enterprise-wide AI adoption and the PPD clinical research business’s AI-enabled offerings across the clinical trial lifecycle.

SUMMARY 

  • Thermo Fisher Scientific was named to Fortune’s 2026 AIQ 75, a ranking of Fortune 500 companies’ adoption and scaling of artificial intelligence. 
  • Thermo Fisher was one of 36 companies added to the expanded 2026 list. 
  • The PPD clinical research business applies AI across the clinical trial lifecycle, from start-up through execution. Its capabilities include predictive insights for protocol, trial, site, and patient decisions, as well as trial monitoring, risk identification, and pharmacovigilance case intake.

Thermo Fisher Scientific, the parent company of the PPD clinical research business, was named to Fortune’s 2026 AIQ 75, a ranking of Fortune 500 companies on how effectively they adopt and scale artificial intelligence, published September 29, 2026 with research partner ETR. Thermo Fisher was one of 36 companies added to the expanded 2026 list, and Fortune cited its rollout of more than 100,000 ChatGPT Enterprise licenses to employees. The recognition follows PPD’s clinical research business being named a Leader among CROs in the 2026 ISG Provider Lens Life Sciences Digital Services report for its use of AI in clinical trials.  

How PPD applies AI in clinical research 

The PPD clinical research business offers digital solutions designed to support clinical trial planning, oversight, and data review. Its digital and AI solutions combine intelligent technology with deep clinical expertise to help sponsors see sooner, decide earlier, and move faster, with demonstrated impact across forecasting, enrollment, contracting, and medical writing. Examples include the Clinical Trial Forecasting Suite supporting forecasting, while Preclarus providing real-time data and visualizations. In pharmacovigilance, PPD SafetyNet Intake uses AI to support safety case intake. 

Thermo Fisher announced a collaboration with OpenAI in October 2025, naming the PPD clinical research business as an initial focus area for applying OpenAI capabilities to improve clinical trial cycle times. 

FAQs 

The Fortune AIQ 75 is Fortune’s 2026 ranking of Fortune 500 companies on how effectively they adopt and scale artificial intelligence. It expanded the inaugural 2025 Fortune AIQ 50 and was produced with research partner ETR.

The list recognizes Thermo Fisher Scientific, the parent company of the PPD clinical research business. It does not separately rank PPD or CROs.

The PPD clinical research business offers digital solutions designed to support clinical trial planning, oversight, and data review. Examples include the Clinical Trial Forecasting Suite supporting forecasting, while Preclarus providing real-time data and visualizations. In pharmacovigilance, PPD SafetyNet Intake uses AI to support safety case intake. 

In May 2026, the PPD clinical research business was named a Leader among CROs in the 2026 ISG Provider Lens Life Sciences Digital Services report. The report recognized the business for clinical development, patient engagement, and AI-driven pharmacovigilance.

Each company’s score is a weighted average of four components: self-report, peer-report, peer-selection, and an AI-agents score added for 2026. ETR surveyed IT decision-makers at Fortune 500 organizations from July 10 through August 11, 2026. Fortune and ETR owned the survey design and ranking calculations.

Under a collaboration announced in October 2025, Thermo Fisher is embedding OpenAI capabilities into its business, with the PPD clinical research business as an initial focus area to improve clinical trial cycle times. Thermo Fisher also launched ChatGPT Enterprise for its colleagues.

The 2026 ISG Provider Lens report says Thermo Fisher applies artificial intelligence and machine learning to safety case processing, signal detection, and regulatory intelligence, supporting proactive risk management and compliance across global markets.

Explore Drug Development Digital Solutions from the PPD clinical research business.